BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget 2017;8:59889-900. [PMID: 28938691 DOI: 10.18632/oncotarget.17431] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
2 Noronha V, Chougule A, Chandrani P, Kaushal RK, Patil VM, Menon N, Kapoor A, Chopade S, Singh A, Shetty O, Dutt A, Banavali S, Prabhash K. Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study. Acta Oncol 2022;:1-5. [PMID: 35972844 DOI: 10.1080/0284186X.2022.2109426] [Reference Citation Analysis]
3 Behel V, Noronha V, Patil V, Menon N, Chandrani P, Kumar R, Rastogi S, Mahajan A, Chougule A, Dutt A, Prabhash K. Molecular tumor board–guided treatment of non-small-cell lung cancer with dual driver (ALK and EGFR) alterations. Cancer Res Stat Treat 2022;5:312. [DOI: 10.4103/crst.crst_114_22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Selvarajan G, Jayachandran PK. Dual driver in non-small cell lung carcinoma – therapeutic dilemma. IJMIO 2021;7:16-19. [DOI: 10.25259/ijmio_22_2021] [Reference Citation Analysis]
5 Nguyen THT, Pham XD, Dao KL, Vo TT. Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation. Case Rep Oncol 2021;14:1085-91. [PMID: 34326746 DOI: 10.1159/000516404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zhao D, Fan J, Peng L, Huang B, Zhu Y, Shi H, Dai X, Nie X. Two different patterns of lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement. Tumori 2021;:3008916211005546. [PMID: 33818198 DOI: 10.1177/03008916211005546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Cipriano É, Magalhães H, Tavares C, Pinto J, Cirnes L, Estevinho F. Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review. Porto Biomed J 2021;6:e124. [PMID: 33884320 DOI: 10.1097/j.pbj.0000000000000124] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Yan G, Zhong X, Pu C, Yue L, Shan H, Lan S, Zhou M, Hou X, Yang J, Li D, Fan S, Li R. Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design. J Med Chem 2021;64:1558-69. [PMID: 33471528 DOI: 10.1021/acs.jmedchem.0c01707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zhang R, Dong L, Yu J. Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors. Front Oncol 2020;10:544579. [PMID: 33520689 DOI: 10.3389/fonc.2020.544579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Fois SS, Paliogiannis P, Zinellu A, Fois AG, Cossu A, Palmieri G. Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. Int J Mol Sci 2021;22:E612. [PMID: 33435440 DOI: 10.3390/ijms22020612] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 11.5] [Reference Citation Analysis]
11 Yan G, Zhong X, Yue L, Pu C, Shan H, Lan S, Zhou M, Hou X, Yang J, Li R. Discovery of a PROTAC targeting ALK with in vivo activity. Eur J Med Chem 2021;212:113150. [PMID: 33453602 DOI: 10.1016/j.ejmech.2020.113150] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
12 Recondo G, Friboulet L. Therapeutic strategies to overcome ALK resistance in lung cancer. Therapeutic Strategies to Overcome ALK Resistance in Cancer 2021. [DOI: 10.1016/b978-0-12-821774-0.00004-8] [Reference Citation Analysis]
13 Beg S, Bareja R, Ohara K, Eng KW, Wilkes DC, Pisapia DJ, Zoughbi WA, Kudman S, Zhang W, Rao R, Manohar J, Kane T, Sigouros M, Xiang JZ, Khani F, Robinson BD, Faltas BM, Sternberg CN, Sboner A, Beltran H, Elemento O, Mosquera JM. Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. Transl Oncol 2021;14:100944. [PMID: 33190043 DOI: 10.1016/j.tranon.2020.100944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
14 Hung YP, Chirieac LR. How should molecular findings be integrated in the classification for lung cancer? Transl Lung Cancer Res 2020;9:2245-54. [PMID: 33209647 DOI: 10.21037/tlcr-20-153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Li J, Kwok HF. Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment. Cancers (Basel) 2020;12:E1587. [PMID: 32549388 DOI: 10.3390/cancers12061587] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
16 Fan J, Wu J, Huang B, Zhu Y, Shi H, Dai X, Nie X. Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report. Diagn Pathol 2020;15:42. [PMID: 32375829 DOI: 10.1186/s13000-020-00969-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dang AH, Tran VU, Tran TT, Thi Pham HA, Le DT, Nguyen L, Nguyen NV, Thi Nguyen TH, Nguyen CV, Le HT, Thi Nguyen ML, Le VT, Nguyen PH, Vo BT, Thi Dao HT, Nguyen LT, Van Nguyen TC, Bui QN, Nguyen LH, Nguyen NH, Thi Nguyen QT, Le TX, Do TT, Dinh KT, Do HN, Phan MD, Nguyen HN, Tran LS, Giang H. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population. Sci Rep 2020;10:2707. [PMID: 32066856 DOI: 10.1038/s41598-020-59744-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
18 Zhao Y, Wang S, Zhang B, Qiao R, Xu J, Zhang L, Zhang Y, Han B. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. Target Oncol 2019;14:169-78. [PMID: 30888598 DOI: 10.1007/s11523-019-00628-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
19 Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol 2019;42:337-44. [PMID: 30741758 DOI: 10.1097/COC.0000000000000508] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
20 Zhu VW, Klempner SJ, Ou SI. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. Trends in Cancer 2019;5:677-92. [DOI: 10.1016/j.trecan.2019.09.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
21 Yu H, Sun S, Hu X, Xia J, Wang J, Chen H. Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer. Onco Targets Ther 2019;12:6481-95. [PMID: 31616158 DOI: 10.2147/OTT.S185115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
22 Hötzel J, Melling N, Müller J, Polonski A, Wolters-Eisfeld G, Izbicki JR, Karstens KF, Tachezy M. Protein expression of close homologue of L1 (CHL1) is a marker for overall survival in non-small cell lung cancer (NSCLC). J Cancer Res Clin Oncol 2019;145:2285-92. [PMID: 31372722 DOI: 10.1007/s00432-019-02989-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
23 Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, Sørensen JB. Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers (Basel) 2019;11:E923. [PMID: 31266248 DOI: 10.3390/cancers11070923] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 16.3] [Reference Citation Analysis]
24 Szpechcinski A, Florczuk M, Duk K, Zdral A, Rudzinski S, Bryl M, Czyzewicz G, Rudzinski P, Kupis W, Wojda E, Giedronowicz D, Langfort R, Barinow-Wojewodzki A, Orlowski T, Chorostowska-Wynimko J. The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients. Cell Mol Life Sci 2019;76:3641-56. [PMID: 30953094 DOI: 10.1007/s00018-019-03089-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
25 Chen M, Xu Y, Zhao J, Zhong W, Zhang L, Bi Y, Wang M. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. EBioMedicine 2019;42:304-10. [PMID: 30878600 DOI: 10.1016/j.ebiom.2019.03.023] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
26 Shin HJ, Kho BG, Kim MS, Park HY, Kim TO, Kim YI, Lim SC, Park CK, Kim YC, Choi YD, Oh IJ. Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series. Medicine (Baltimore) 2019;98:e14699. [PMID: 30817606 DOI: 10.1097/MD.0000000000014699] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
27 Li P, Gao Q, Jiang X, Zhan Z, Yan Q, Li Z, Huang C. Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma. J Cancer 2019;10:61-71. [PMID: 30662526 DOI: 10.7150/jca.26947] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
28 Purkayastha A, Kapoor A, Singh HP, Sarin A, Sengupta P, Singh S, Bisht N, Husain A. Concomitant expression of exon 19 mutation epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangement in metastatic adenocarcinoma lung responsive to crizotinib. Lung India 2018;35:527-9. [PMID: 30381567 DOI: 10.4103/lungindia.lungindia_30_18] [Reference Citation Analysis]
29 Hung YP, Sholl LM. Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. Adv Anat Pathol 2018;25:374-86. [PMID: 30188361 DOI: 10.1097/PAP.0000000000000206] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
30 . Antineoplastics. Reactions Weekly 2017;1675:39-39. [DOI: 10.1007/s40278-017-37807-1] [Reference Citation Analysis]